[{"orgOrder":0,"company":"Institut National De La Recherche Agronomique","sponsor":"National Research Agency, France | Solvay","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Institut National De La Recherche Agronomique","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut National De La Recherche Agronomique \/ National Research Agency, France | Solvay","highestDevelopmentStatusID":"1","companyTruncated":"Institut National De La Recherche Agronomique \/ National Research Agency, France | Solvay"},{"orgOrder":0,"company":"Ohio State University","sponsor":"The University of Pittsburgh School of Medicine | University of Illinois, Chicago | University of Southern California | New York University | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Ohio State University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ohio State University \/ The University of Pittsburgh School of Medicine | University of Illinois, Chicago | University of Southern California | New York University | AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"Ohio State University \/ The University of Pittsburgh School of Medicine | University of Illinois, Chicago | University of Southern California | New York University | AbbVie Inc"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"AbbVie Inc | National Institute of Diabetes and Digestive and Kidney Diseases | Phoenix Indian Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Children's Hospital of Philadelphia \/ AbbVie Inc | National Institute of Diabetes and Digestive and Kidney Diseases | Phoenix Indian Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Children's Hospital of Philadelphia \/ AbbVie Inc | National Institute of Diabetes and Digestive and Kidney Diseases | Phoenix Indian Medical Center"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Philadelphia \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Children's Hospital of Philadelphia \/ AbbVie Inc"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2011","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Nuvisan GmbH | Datamap | ClinIntel | Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abbott Laboratories \/ Nuvisan GmbH | Datamap | ClinIntel | Catalent Pharma Solutions","highestDevelopmentStatusID":"11","companyTruncated":"Abbott Laboratories \/ Nuvisan GmbH | Datamap | ClinIntel | Catalent Pharma Solutions"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Actavis Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Actavis Inc","highestDevelopmentStatusID":"11","companyTruncated":"Beth Israel Deaconess Medical Center \/ Actavis Inc"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Endocrinology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Endocrinology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"AbbVie Inc | LKF Laboratorium f\u00fcr Klinische Forschung | Analytical Biochemical Laboratory | Parexel | Datamap | Linical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Endocrinology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ AbbVie Inc | LKF Laboratorium f\u00fcr Klinische Forschung | Analytical Biochemical Laboratory | Parexel | Datamap | Linical","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ AbbVie Inc | LKF Laboratorium f\u00fcr Klinische Forschung | Analytical Biochemical Laboratory | Parexel | Datamap | Linical"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Allergan"},{"orgOrder":0,"company":"Massimo Raimondo, M.D.","sponsor":"Digestive Care","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Massimo Raimondo, M.D.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massimo Raimondo, M.D. \/ Digestive Care","highestDevelopmentStatusID":"7","companyTruncated":"Massimo Raimondo, M.D. \/ Digestive Care"},{"orgOrder":0,"company":"Vivus","sponsor":"Andrew Hendifar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Oncology","graph2":"Phase II","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vivus \/ Andrew Hendifar","highestDevelopmentStatusID":"8","companyTruncated":"Vivus \/ Andrew Hendifar"}]
Find Clinical Drug Pipeline Developments & Deals for Pancrelipase
Details :
CREON (pancrelipase) is prescription medicine used to treat people who cannot digest food normally because their pancreas does not make enough enzymes due to cystic fibrosis, swelling of pancreas that lasts a long time, removal of some or all of pancreas...
Details :
Pancrelipase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cystic Fibrosis.
Details :
Pancrelipase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Exocrine Pancreatic Insufficiency.
Details :
Pancrelipase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cystic Fibrosis.
Details :
Pancrelipase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Exocrine Pancreatic Insufficiency.
Sponsor :
The University of Pittsburgh School of Medicine | University of Illinois, Chicago | University of Southern California | New York University | AbbVie Inc
Details :
Pancrelipase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Exocrine Pancreatic Insufficiency.
Sponsor :
The University of Pittsburgh School of Medicine | University of Illinois, Chicago | University of Southern California | New York University | AbbVie Inc
Details :
Pancrelipase is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatic Neoplasms.
Details :
Pancrelipase is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatic Neoplasms.
Details :
Pancrelipase is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Exocrine Pancreatic Insufficiency.
Details :
Creon (Pancrelipase) is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Short Bowel Syndrome.
Reset All
